SCHEMBL1692140

SCHEMBL1692140

COCC1(c2ccccc2)CO1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.40
ADRA1D P25100 1/20 0.39
CYP2C19 P33261 2/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CHRM2 P08172 2/20 0.34
CHRM4 P08173 2/20 0.34
CHRM1 P11229 2/20 0.34
CHRM3 P20309 2/20 0.34
DPP4 P27487 1/20 0.34
CHRNB2 P17787 1/20 0.34
SLC6A2 P23975 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA4 P43681 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11702282 0.83 HTR1A (0.38) HTR1AADRA1DTSHRMAPK1SMN1; SMN2
SCHEMBL2729452 0.81 HTR1A (0.38) HTR1AADRA1DTSHRMAPK1SMN1; SMN2
SCHEMBL11264607 0.78 HTR1A (0.48) HTR1AADRA1DADRA1A
SCHEMBL1667453 0.78 HTR1A (0.39) HTR1AADRA1DCYP2C19CYP2C9TSHR
SCHEMBL6493726 0.77 MEN1 (0.40) HTR1ATSHRCHRM2CHRM4CHRM1
SCHEMBL6493723 0.77 MEN1 (0.40) HTR1ATSHRCHRM2CHRM4CHRM1
SCHEMBL1692387 0.74 CYP2C19 (0.41) HTR1ACYP2C19CYP3A4CYP2C9CHRM1
SCHEMBL476332 0.74 ADRA1D (0.46) HTR1AADRA1DMAPK1SMN1; SMN2L3MBTL1
SCHEMBL3682203 0.74 CYP2C19 (0.32) CYP2C19CYP3A4CYP2C9
SCHEMBL8806111 0.73 CHRM2 (0.38) HTR1ACHRM2CHRM4CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722662-B2 Heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-05-13 US disclosed
US-20130267494-A1 1,4-OXAZEPANE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-10-10 US disclosed
US-20120088748-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267494-A1 1,4-OXAZEPANE DERIVATIVES MAOB, SLC6A4, SLC6A2 HTR1A 26/4885ADRA1D 117/4885CYP2C19 30/4885
US-20120088748-A1 HETEROCYCLIC COMPOUNDS SLC6A2, MAOB, MAOA HTR1A 20/4885ADRA1D 106/4885CYP2C19 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.